This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Chicago, IL –July 19, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Netflix (NFLX - Free Report) , Eli Lilly (LLY - Free Report) , BNY Mellon (BK - Free Report) , TJX Companies (TJX - Free Report) and Raytheon (RTN - Free Report) .
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Eli Lilly (LLY) and BNY Mellon (BK). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
NS.PRC NS.PRB HD TJX SYK NFLX NS NS.PRA ROK
Headlines about the death of the American shopping mall have become so common that the phrase "retail apocalypse" has its own Wikipedia page. But this is a death wrongly foretold - and that creates investment opportunities.
SHLD TJX JCP M SHLDW
Good news for CA, Inc. (NASDAQ:CA) shareholders was bad news for Broadcom (NASDAQ:AVGO) owners. The latter is looking to acquire the former, sending CA shares up a healthy 18.6%. The market is ultimately saying Broadcom is overpaying for the headache of integrating the two companies, however, as AVGO shares ended Thursday’s action in the red to the tune of 13.7%.
TJX JWN AVGO KSU.PR NYTAB CA KSU
Looking for broad exposure to the Large Cap Blend segment of the US equity market? You should consider the First Trust Capital Strength ETF (FTCS - Free Report) , a passively managed exchange traded fund launched on 07/06/2006.
EXPD TJX IVV WCG IVV
In the last few weeks, Barnes & Noble (NYSE:BKS) has experienced its fair share of headaches. First, the company posted terrible Q4 results as comps declined 4.1% y/y and a loss of $21.1 million – down $8 million from last year’s result. Then, on July 3rd, CEO Demos Parneros was terminated for violating the company’s policies. We don’t know exactly what this is, but Parneros is receiving no termination compensation.
TJX TGT AMZN SBUX BKS BBY WMT ROST
The retail landscape has been undergoing a fundamental change with technology playing a major role and the focus shifting to online shopping. This shift in buying pattern has compelled retailers to come up with innovative ways to market their products.
TJX BURL ROST
The retail landscape has been undergoing a fundamental change with technology playing a major role and the focus shifting to online shopping. This shift in buying pattern has compelled retailers to come up with innovative ways to market their products. Retailers who have responded quickly to it by staying ahead technologically stand in good stead. Be it department stores, discount retailers, supermarket chains or grocery players, all are in the race of survival of the fittest.
TJX BURL ROST
Several events have occurred at Under Armour (NYSE:UAA) (NYSE:UA) since I last wrote about the then-struggling athletic apparel giant. Shares are now over $20, and I believe the market feels much more confident in the company’s prospects. C-Shares traded around $16, and the situation today is clearly improved in many ways. That being said, I believe Under Armour’s financial situation undeniably involves at least three more quarters of heavy discounting.
GCO UA TJX NKE UAA ROST EBAY
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to TJX / TJX Companies, Inc. (The) on message board site Silicon Investor.
|TJX Companies (TJ Maxx, etc.)||TJX still going strong|
as of ET